{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:24:15Z","timestamp":1791537855824,"version":"4.3.4"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anamorelin is a ghrelin receptor agonist that can be administered orally and thought to improve cancer cachexia by improving appetite and increasing serum insulin\u2010like growth factor\u20101. Anamorelin was not approved for use in Europe. In contrast, the use of anamorelin for cancer cachexia in four types of cancer (non\u2010small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer) was approved in Japan on 11 December 2020. Phase 2 trial (ONO\u20107643\u201004) for the treatment of patients with non\u2010small cell lung cancer and cachexia resulted in 1.56\u00a0kg lean body mass increase assessed by dual\u2010energy X\u2010ray absorptiometry (DXA). Another study for advanced and unresectable gastrointestinal (colorectal, gastric, or pancreatic) cancer showed 1.89\u00a0\u00b1\u00a00.36\u00a0kg improvement in lean body mass. Skeletal lean body mass assessed by DXA is important for diagnosing sarcopenia and cachexia in Asia. The approval of anamorelin is expected to change clinical practice of cancer cachexia in Japan and hopefully in other countries. In the past, cachexia was rarely diagnosed in Japan, because it was often thought that cachexia meant terminal stage. The dissemination of clinical findings on anamorelin from Japan, as well as the creation of consensus papers and clinical practice guidelines for cachexia in Japan and Asia, will be required to promote international expansion in the future.<\/jats:p>","DOI":"10.1002\/jcsm.12675","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T05:58:29Z","timestamp":1609394309000},"page":"14-16","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["The regulatory approval of anamorelin for treatment of cachexia in patients with non\u2010small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers."],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-0818","authenticated-orcid":false,"given":"Hidetaka","family":"Wakabayashi","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine Tokyo Women's Medical University Hospital  8\u20101, Kawada\u2010cho, Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[{"name":"National Center for Geriatrics and Gerontology  Obu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Inui","sequence":"additional","affiliation":[{"name":"Pharmacological Department of Herbal Medicine Kagoshima University Graduate School of Medical &amp; Dental Sciences  Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"e_1_2_4_2_1","first-page":"9","article-title":"Human growth hormone available for AIDS wasting","volume":"9","author":"Gilden D","year":"1995","journal-title":"GMHC Treat Issues"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00611"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12063"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/45230"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31128"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32406"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx192"},{"key":"e_1_2_4_10_1","unstructured":"Refusal of the marketing authorisation for adlumiz (anamorelin hydrochloride). EMA\/305706\/2017 rev1 (2017) EMEA\/H\/C\/003847"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3144-z"},{"key":"e_1_2_4_12_1","unstructured":"Pharmaceutical Affairs and Food Sanitation Council First Committee on Drugs Japan's first cancer cachexia drug Edlumiz approved after second round of deliberations. Mix Online.https:\/\/www.mixonline.jp\/tabid55.html?artid=70308Accessed 17 Dec 2020. [In Japanese]"},{"key":"e_1_2_4_13_1","unstructured":"Pharmaceutical Affairs and Food Sanitation Council First Committee on Drugs. The Ministry of Health Labor and Welfare.https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi\u2010yakuji_127851.htmlAccessed 17 Dec 2020. [In Japanese]"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16372"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2019.12.012"},{"key":"e_1_2_4_16_1","first-page":"167","article-title":"Sarcopenia and cachexia evaluation in different healthcare settings: a questionnaire survey of health professionals","volume":"27","author":"Nakahara S","year":"2018","journal-title":"Asia Pac J Clin Nutr"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12525"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-014-0162-x"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmaa111"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12083"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12501"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12675","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcsm.12675","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:25:44Z","timestamp":1693632344000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.12675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/jcsm.12675"],"URL":"https:\/\/doi.org\/10.1002\/jcsm.12675","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"2020-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}